Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

The true costs of administering infliximab to patients with Crohn's disease (CD) are likely to be lower in clinical practice than those reported for charged amounts,

    • 13 Accesses

    This is a preview of subscription content, log in to check access.

    REFERENCE

    1. 1.

      Ollendorf DA, Lidsky L.Infliximab drug and infusion costs among patients with Crohn's disease in a commercially-insured setting. American Journal of Therapeutics 13: 502-506, No. 6, Nov-Dec 2006

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    The true costs of administering infliximab to patients with Crohn's disease (CD) are likely to be lower in clinical practice than those reported for charged amounts,. Pharmacoecon. Outcomes News 521, 5 (2007). https://doi.org/10.2165/00151234-200705210-00013

    Download citation

    Keywords

    • Public Health
    • Clinical Practice
    • Health Outcome
    • Infliximab
    • Health Economic